Corbus Pharma plunges 60% following Novo Nordisk weight loss drug data

Adam Gault/OJO Images via Getty Images Corbus Pharmaceuticals ( NASDAQ: CRBP ) is down 60% in Friday trading as an apparent casualty of disappointing results from a Novo Nordisk ( NVO ) phase 2 trial on oral weight loss candidate monlunabant. Corbus is developing CRB-913 for obesity, a compound with a mechanism of action.